Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by three phases: chronic, accelerated, and blast phase. However; first- and second-generation tyrosine kinase inhibitors are used for the treatment of CML with common and uncommon adverse events. Here, we report a 24-year-old male with CML in chronic phase started on imatinib as upfront medication who developed tremor and recovered spontenously after 3 years.
Keywords: Chronic myeloid leukemia; Imatinib; Side effects; Tremor; Tyrosine kinases.
Copyright © 2019 by S. Karger AG, Basel.